These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33523913)

  • 41. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
    Thibault C; Nelson H; Chapoval AI
    Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
    Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
    Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
    Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration.
    Li L; Nian S; Liu Q; Zhang B; Jimu W; Li C; Huang Z; Hu Q; Huang Y; Yuan Q
    Int Immunopharmacol; 2024 May; 132():111926. PubMed ID: 38552297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
    Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
    J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
    Compte M; Harwood SL; Muñoz IG; Navarro R; Zonca M; Perez-Chacon G; Erce-Llamazares A; Merino N; Tapia-Galisteo A; Cuesta AM; Mikkelsen K; Caleiras E; Nuñez-Prado N; Aznar MA; Lykkemark S; Martínez-Torrecuadrada J; Melero I; Blanco FJ; Bernardino de la Serna J; Zapata JM; Sanz L; Alvarez-Vallina L
    Nat Commun; 2018 Nov; 9(1):4809. PubMed ID: 30442944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
    Al-Sukaini A; Hornicek FJ; Peacock ZS; Kaban LB; Ferrone S; Schwab JH
    Clin Orthop Relat Res; 2017 Dec; 475(12):3071-3081. PubMed ID: 28725958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
    Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
    Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
    Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
    J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy.
    Chen YL; Cui Y; Liu X; Liu G; Dong X; Tang L; Hung Y; Wang C; Feng MQ
    J Biol Chem; 2021 Dec; 297(6):101420. PubMed ID: 34798072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune-Checkpoint Blockade Opposes CD8
    Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
    Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.
    Guo L; Liu Z; Zhang Y; Quan Q; Huang L; Xu Y; Cao L; Zhang X
    Medicine (Baltimore); 2019 Feb; 98(8):e14663. PubMed ID: 30813210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells.
    Shen A; Liu W; Wang H; Zeng X; Wang M; Zhang D; Zhao Q; Fang Q; Wang F; Cheng L; Shen G; Li Y
    Am J Cancer Res; 2023; 13(7):3246-3256. PubMed ID: 37559991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
    Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
    Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
    Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
    Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. B7-H3 and B7-H4 Expression in Breast Cancer and Their Association with Clinicopathological Variables and T Cell Infiltration.
    Kim NI; Park MH; Kweon SS; Lee JS
    Pathobiology; 2020; 87(3):179-192. PubMed ID: 32088722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.
    Brunner A; Hinterholzer S; Riss P; Heinze G; Brustmann H
    Gynecol Oncol; 2012 Jan; 124(1):105-11. PubMed ID: 21982044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.